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HTNV infection is mediated by αvβ3 integrin. We used protein blots of Vero E6 cell homogenates to
demonstrate that radiolabeled HTNV virions bind to gC1qR/p32, the acidic 32-kDa protein known as the
receptor for the globular head domain of complement C1q. RNAi-mediated suppression of gC1qR/p32
markedly reduced HTNV binding and infection in human lung epithelial A549 cells. Conversely, transient
expression of either simian or human gC1qR/p32 rendered non-permissive CHO cells susceptible to HTNV
infection. These results suggest an important role for gC1qR/p32 in HTNV infection and pathogenesis.
© 2008 Elsevier Inc. All rights reserved.IntroductionHantaan virus (HTNV) is a highly pathogenic hantavirus that
causes hemorrhagic fever with renal syndrome (HFRS) in humans
(Schmaljohn and Nichol, 2007). Transmission of HTNV to humans
occurs by inhalation of the aerosolized excreta of infected rodents.
Pathogenic features of the disease include generalized capillary
damage leading to drastic alteration in the permeability of the
vascular endothelium (Klein and Calisher, 2007). HTNV does not lyse
endothelial cells, so it is unclear how HTNV infection changes vascular
permeability.
The in vitro study of HTNV replication is limited to a few cultured
cell lines (French et al., 1981), and the reason for this restriction
remains unknown. HTNV utilizes integrin αvβ3 during the cell entry
process (Gavrilovskaya et al., 1999). Recently, the GPI-anchored
protein DAF/CD55 was shown to mediate HTNV entry across the
apical membrane of polarized epithelial cells (Krautkramer and Zeier,
2008). Other cellular proteins have also been implicated in HTNV
entry (Kim et al., 2002; Mou et al., 2006).
The protein gC1qR/p32 (also called p33 or HABP-1) is a 32-kDa
glycoprotein that was initially shown to bind the globular “head”
domain of the complement protein C1q (Peerschke et al., 1994).
Expressed in many cell types including endothelial cells, dendritic
cells, lymphocytes, and platelets, the receptor shows afﬁnity for a
broad range of plasma and cellular proteins, including thrombin,iotechnology, Korea University,
82 2 923 9923.
l rights reserved.vitronectin, high molecular weight kininogen, and hyaluronic acids
(Deb and Datta, 1996; Ghebrehiwet and Peerschke, 1998; Herwald
et al., 1996). The gC1qR/p32 protein also reportedly interacts with a
number of viral proteins, such as the hepatitis C viral core, the rubella
viral capsid, IE63 of the herpes simplex virus type-1, EBNA1 of Epstein–
Barr virus, adenovirus polypeptide V, and Rev and Tat of HIV-1
(Ghebrehiwet and Peerschke, 2004). The gC1qR/p32 protein is also
utilized for the attachment or entry of microbial pathogens such as
Listeria monocytogenes, Staphyloccus aureus, and Plasmodium falci-
parum (Braun et al., 2000; Nguyen et al., 2000; Biswas et al., 2007).
In the present study, we demonstrate that gC1qR binds to HTNV
and mediates viral infection in cell culture.
Results
HTNV binding of gC1qR/p32
In order to identify the cellular proteins that interact with HTNV,
membrane proteins were isolated from Vero E6 cells, separated by
denaturing gel electrophoresis, blotted onto a nitrocellulose mem-
brane, and incubated in a solution of [35S]-labeled HTNV virions. A
protein band corresponding to a molecular weight of ∼32 kDa was
visualized by autoﬂuorography (Fig. 1A). The exact identities of the
proteins forming this band could not be determined from this sample
due to insufﬁcient material. More material was resolved using a 2-D
gel electrophoresis technique, and the virion-binding assay was
repeated. A spot corresponding to a molecular weight of ∼32 kDa
with a pI ∼4.7 was visualized by autoﬂuorography (Fig. 1B). The gel
was stained, and the 32-kDa protein was extracted, trypsinized, and
subjected toMS/MS analysis. Sequencing of a unique peptide fragment
Fig. 1. Identiﬁcation of HTNV binding proteins. (A) Vero E6 cell membrane proteins (∼40 μg) were resolved by electrophoresis on a denaturing 4–20% polyacrylamide gel. The
Coomassie Blue-stained gel (lane 1) and the autoﬂuorograph of the nitrocellulose membrane strips probed with [35S]-methionine-labeled HTNV (lane 2) are shownwith protein size
markers on the left. (B) Cell membrane proteins (∼185 μg) were resolved by isoelectrofocusing followed by denaturing gel electrophoresis. The Coomassie Blue-stained gel (upper
panel) and an autoﬂuorograph of a virus-bound blot (lower panel) are shown. The position of the 32-kDa HTNV-bound protein is indicated.
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acidic and ubiquitous protein known as the receptor for the globular
“head” domain of complement protein C1q. We conﬁrmed the results
of the virion-binding assay by repeating the 2-D gel separation and
then immunoblotting the gel with a gC1qR/p32 antibody. The
antibody speciﬁcally recognized the 32-kDa protein in the 2-D gel
blot at the corresponding position of the virion-binding assay (data
not shown). We also conﬁrmed that the gC1qR/p32 protein in the blot
does not bind [35S]-labeled mock fractions prepared from uninfected
cells.
Roles of gC1qR/p32 for HTNV infection
In order to investigate the interaction between HTNV and gC1qR/
p32 during the viral infection process, we used siRNA to suppress
gC1qR/p32 expression. We have chosen human lung epithelial A549
cells for this experiment since respiratory epithelium is the primary
target of HTNV and this cell line supports HTNV infection as efﬁciently
as Vero E6 cells in vitro. Two independent cell cloneswere established,
each stably expressing siRNA targeting the gC1qR/p32mRNA sequence
at either the junction of exons 1 and 2 or exon 3. Viral binding was
tested by incubating pre-chilled cells with HTNV at a multiplicity ofFig. 2. HTNV binding of gC1qR/p32-siRNA cells. Human A549 cells expressing gC1qR/
p32 siRNA (targeting exon 3 or the junction of exon 1 and 2) were pre-chilled and
incubated with HTNV (MOI=1) for 2 h at 4 °C in serum-free medium. After washing
several times at 4 °C, cell-bound virus was quantitated by immunoblotting of viral N
protein. Also probed were gC1qR/p32, and actin as a loading control. Cells expressing
either no siRNA or an unrelated siRNA (pSilencer) were also analyzed for comparison.infection (MOI) of 1 for 2 h at 4 °C. After several washes, the extent of
viral adsorptionwas subsequently assessed by immunoblotting for the
viral nucleocapsid N protein. A substantial amount of virus remainedFig. 3. HTNV infection of gC1qR/p32-siRNA cells. (A) N protein levels in HTNV-infected
A549 cells (MOI=1) and in the culture mediumwere determined by immunoblotting at
the times indicated. (B) HTNV titer in the culture medium at the times indicated
was determined by plaque assay with Vero E6 cells. (C) Infection of NDV in A549
cells (MOI=10) was determined by immunoblotting of cell lysate for recombinant
NDV-encoded GFP expression. Hsp70 expression was used as a control.
Fig. 4. Immunostaining of gC1qR/p32. (A) Vero E6 cells ﬁxed with paraformaldehyde were incubated with gC1qR/p32 antibody followed by FITC-conjugated secondary antibody. The
cells were stained with 0.1 μg/ml of DAPI and observed under a ﬂuorescence microscope. (B) Vero E6 cells co-transfected with human gC1qR/p32 and pDsRed1-mito were probed
with anti-HA antibody and FITC-conjugated secondary antibody. The two images are combined on the right.
Fig. 5. Biotinylation of gC1qR/p32. Biotin-labeled Vero E6 cells were lysed and
membrane proteins were extracted and afﬁnity-puriﬁed with streptavidin agarose
beads. Eluted proteins were separated by gel electrophoresis and immunoblotted with
gC1qR/p32 antibody (lane 4). Proteins from cells without biotin labeling were afﬁnity-
puriﬁed as a control (lane 2). Cell lysate prior to the afﬁnity step (∼5% of total lysate) was
loaded for comparison: unlabeled (lanes 1); biotin-labeled (lane 3).
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expressing an unrelated siRNA. In contrast, viral binding was barely
detectable on the surface of both cell lines expressing gC1qR/p32
siRNA (Fig. 2). Expression of gC1qR/p32 was almost completely
suppressed in those cells while that of actin was unaffected.
In order to further investigate the role of gC1qR/p32 in HTNV
infection, control A549 cells and the two cell lines expressing gC1qR/
p32 siRNA were infected with HTNV. A rapid synthesis of N protein
was observed in the control cells after 24 h. In contrast, the levels of N
protein in siRNA-expressing cell lines were ∼5% those of control cells
(Fig. 3A). The viral titer in the culture media of the siRNA-expressing
cell lines was lower than that of control cells by ∼10-fold at 48 h and
∼100-fold at 76 h, respectively (Fig. 3B). These results demonstrate
that gC1qR/p32 is required for efﬁcient HTNV infection.
To estimate the speciﬁcity of gC1qR/p32 for HTNV, we tested the
infection of NewCastle Disease Virus in the A549 cells carrying gC1qR/
p32 siRNA. NDV infection assessed by the expression of recombinant
virus-encoded GFP (Park et al., 2003) was not affected by gC1qR/p32
knockdown (Fig. 3C). It is of note that HTNV binding of the
immobilized gC1qR/p32 was not affected by co-incubation with
polio virus preparation in our previous study (Kim et al., 2002).
Cellular distribution of gC1qR/p32
Present in a wide range of cell types including lymphocytes,
neutrophils, hepatocytes, and endothelial cells, gC1qR/p32 has been
found in mitochondria, in the nucleus, at the cell membrane, and in
the extracellular matrix (Ghebrehiwet et al., 1995; Peterson et al.,
1997). Cellular distribution of gC1qR/p32 in Vero E6 cells was
examined by immunoﬂuorescence assay. The assay showed the
pattern typical of mitochondrial localization for the endogenous
gC1qR/p32 (Fig. 4A), as reported by other investigators (Dedio et al.,
1998). Vero E6 cells transfected with a full-length human gC1qR/p32
cDNA also showed a pattern of mitochondrial localization of the
recombinant protein, virtually overlapped with that of the co-
transfected marker protein, pDsRed1-mito (Fig. 4B). These results
indicate that the majority of gC1qR/p32 is localized in the mitochon-
dria. In order to assess the distribution of gC1qR/p32 on the cell
surface Vero E6 cells were treated with sulfo-NHS-LC-biotin, a
membrane-impermeable compound that attaches biotin moieties toaccessible lysine residues on the cell surface. Biotinylated proteins
were extracted, afﬁnity-puriﬁed, and immunoblotted with antibody
against gC1qR/p32. Biotin-labeled gC1qR/p32 was detected in the
afﬁnity-puriﬁed fraction, whereas no gC1qR/p32 was puriﬁed from
unlabeled cells. From the intensity of bands afﬁnity-puriﬁed gC1qR/
p32was estimated to be ∼2% of the total gC1qR/p32 present in the cell
lysate (Fig. 5).
Expression of gC1qR/p32 in CHO cells
The effect of gC1qR/p32 expression on viral infection was
investigated through transient expression of heterologous gC1qR/
p32 in HTNV-non-permissive CHO cells. CHO cells were transfected
with either simian or human gC1qR/p32 constructs, incubated for
24 h, and infected with HTNV. At 48 h post-infection, cells expressing
either the human or the simian gC1qR/p32 constructs produced 36 to
50% more N protein than control cells (Fig. 6A). Viral titer in the
culture media of gC1qR/p32-expressing cells at 48 h post-infection
Fig. 6. HTNV infection of CHO cells. (A) CHO cells transfected with simian (S) or human
(H) gC1qR/p32 were infected with HTNV (MOI=1), and cell-associated N protein was
analyzed by immunoblotting at the times indicated. Transiently expressed gC1qR/p32
was also measured by immunoblotting with anti-HA antibody. Cellular GAPDH was
used as a loading control. (B) HTNV titer in the culture medium at 48 h post-infection
was determined by plaque assay.
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expression of simian or human gC1qR/p32 rendered CHO cells
susceptible to HTNV infection. However, despite gC1qR/p32 expres-
sion N protein expression in CHO cells was transient: it increased on
day 2 but declined on day 3. Viral titer in the culture media also
peaked on day 2. This result reﬂects the non-permissive nature of CHO
cells for HTNV replication. The effect of gC1qR/p32 expression was
more signiﬁcant in the early stage of infection, probably in the viral
uptake process. We observed a similar effect in CHO cells stably
expressing gC1qR/p32 (data not shown), further suggesting that this is
not due to the transient expression of gC1qR/p32 in this cell.
Discussion
In this study, we demonstrated that efﬁcient HTNV binding and
infection depends on gC1qR/p32 expression. To our knowledge, this is
the ﬁrst investigation to report gC1qR/p32 binding to intact virions of
enveloped viruses. In the previous study we reported the binding of
radiolabeled HTNV virions with a ∼30-kDa Vero E6 cell protein (Kim
et al., 2002). Although speciﬁcity of the virus and cell interaction was
demonstrated in the study, we were unable to determine the identity
of the protein due to insufﬁcient materials and limited resolution of
regular gel electrophoresis. In the present study, we identify that the
∼30-kDa protein is the gC1qR/p32 through MS/MS analysis of a 2-D
gel and immunoblotting with a speciﬁc antibody.
Our immunostaining showed that gC1qR/p32 is mainly localized in
the cytoplasm, particularly in themitochondria. However, the result of
our biotin labeling was consistent with previous investigations
showing localization of some gC1qR/p32 on the cell surface (Eggleton
et al., 1995; Gupta et al., 1991). Although gC1qR/p32 has notransmembrane domain, it is thought to locate on the cell surface
through interactions with other membrane-bound proteins or
components. For example, the lateral association of gC1qR/p32 with
β1 integrin has been suggested in C1q-mediated cell adhesion and
spreading (Feng et al., 2002).
X-ray crystallography studies indicated that gC1qR/p32 protein
possesses a trimeric doughnut-shaped structure with a central
channel approximately 20 Å in diameter (Jiang et al., 1999). The
highly acidic N-terminus of gC1qR/p32 contains a binding site for
C1q and mediates binding of the heparin-binding form of vitronectin
(Lim et al., 1996). Our attempt to block HTNV binding of gC1qR/p32
with soluble C1q or gC1qR/p32 antibodies (such as clone 60.11,
which binds aa 76–93 or clone 74.5.2, which binds aa 203–218 of
gC1qR/p32) did not inhibit HTNV infection (data not shown).
Although these results indicate that the HTNV binding site is
distinct from that of C1q binding, elucidation of the gC1qR/p32
domains responsible for HTNV binding and viral proteins involved
requires further study.
Virus binding to the cell surfacemay also trigger signaling cascades
in the host cell. Hepatitis C virus core protein has been proposed to
modulate host immune responses by binding to gC1qR/p32 expressed
on T-cells and activating the ERK/MEK signaling pathway (Yao et al.,
2001). Given the hemorrhagic characteristic of HTNV infection, it is
tempting to speculate that the binding of HTNV to gC1qR/p32 is
involved in dysregulation of the complement pathway. Although our
results demonstrate that gC1qR/p32 mediates HTNV binding and
infection, whether and how the protein is involved in the pathogen-
esis of HFRS remains a challenging issue.
Materials and methods
Cell and virus samples
African green monkey kidney Vero E6 cells (CRL 1586) were grown
in DMEM (Sigma). Human lung carcinoma A549 (CCL 185) and
Chinese hamster ovary (CHO) (CRL 9096) cells were grown in RPMI
1640 (Sigma), supplemented with 10% FBS, 100 μg/ml streptomycin,
and 100 U/ml penicillin (Invitrogen). For viral infections, cells were
incubated in the presence of HTNV (76–118) in serum-freemedium for
1.5–2 h, after which the medium was replaced with fresh medium
containing 10% FBS. Viral titer was measured by plaque assay using
Vero E6 cells (Kang et al., 1999). HTNV virions were labeled with
[35S]-methionine and puriﬁed from culture media by sucrose gradient
centrifugation as previously described (Kim et al., 2002).
Viral binding to cellular protein blots
Vero E6 cells (∼1.5×108) were harvested and lysed with 15
strokes of a Dounce homogenizer at 4 °C in 10 ml of buffer [20 mM
Tris–HCl (pH 7.5), 100 mM NaCl, 10 mM KCl, 1.5 mM MgCl2, 10 mM
HEPES, and 1% protease inhibitor cocktail (Roche)]. After removal of
cell nuclei by centrifugation at 100 g for 5 min, the microsomal and
membrane fractions were separated by centrifugation at 20,000 g for
30 min at 4 °C. The resulting pellet was resuspended in ReadyPrep
rehydration/sample buffer (Bio-Rad) (8 M urea, 2% CHAPS, 50 mM
DTT, and 0.2% Bio-Lyte 3/10 ampholytes). For 2-D gel analysis,
∼185 μg of protein was applied to a ReadyStrip pH-gradient strip (pH
3–10) at room temperature, incubated overnight, and subjected to
isoelectric focusing in a Protean IEF cell (Bio-Rad) in which the
following cycles were applied: 250 V for 20 min, 8000 V in a linear
ramp for 2.5 h, and 8000 V for 5.3 h. The electrofocused strip was
placed on duplicate 4–20% polyacrylamide gels and separated by
standard electrophoresis under denaturation conditions. One gel was
blotted onto a nitrocellulose membrane (Schleicher and Schuell) for
the viral binding assay, and the other was stained with Coomassie
Blue R-250.
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4 °C in PBS supplementedwith4%BSA andblockedwith5% skimmilk in
PBS for 1 h. After three washes with PBS, the membranewas incubated
overnight at room temperature with [35S]-labeled HTNV (∼1×106 c.p.
m.) in MEM supplemented with 10% FBS. After three,15-minwashes in
PBS supplemented with 2% BSA and one wash in PBS supplemented
with 0.1% NP-40, the membrane was dried and viral binding was
visualized by autoﬂuorography. Proteins showing virus binding were
trypsinized, and peptide sequences were determined by ESI-MS/MS
analysis (In2gen, Korea). Homologous protein sequences present in the
NCBI database were searched using the MASCOT program.
Subcloning of gC1qR/p32 cDNA and siRNA
The gC1qR/p32 cDNAwas ampliﬁed, respectively, from a HeLa cell
cDNA library and Vero E6 cell mRNA using primers based on the
sequences of the genes from humans (AF338439) and monkeys
(X75913) (Beatch and Hobman, 2000; Ghebrehiwet et al., 1994). For
transient expression, the entire protein coding sequence (282 aa for
HeLa or 281 aa for Vero E6 cells) and a C-terminal HA epitope tag
(LEPYDVPDY) subcloned in the pcDNA3 (Invitrogen) was transfected
into cells using Lipofectamine PLUS (Invitrogen). An A549 cell line
expressing gC1qR/p32 siRNA was established by transfection with
pSilencer 2.1-U6 puro (Ambion) containing one of two distinct 21-bp
antisense sequences targeting the gC1qR/p32 mRNA (NM_001212).
One antisense sequence targeted the junction between exons 1 and 2
(5′-aaagct ttgtct ccgtcg gtg) and the other targeted exon 3 (5′-tcaaat
gttggt gggatg ctg). Independent colonies were isolated after incuba-
tion for 3 weeks in medium containing 1 μg/ml puromycin, and
gC1qR/p32 expression was analyzed by immunoblotting.
Immunoﬂuorescence and immunoblotting assays
To verify the expression of gC1qR/p32, cells grown on a chamber
slide were ﬁxed with 3.7% paraformaldehyde in PBS for 15 min at
room temperature. After blocking for 10 min in PBS supplemented
with 1% BSA and 0.1% Tween 20, cells were treated for 1 h with gC1qR/
p32 antibody (Santa Cruz), washed three times in PBS, and incubated
for 30 min with FITC-conjugated secondary antibodies (Sigma). The
cells were mounted with Fluoroguard antifade solution (Bio-Rad) and
observed under an Axioskop2-Plus microscope (Zeiss). Cellular image
was processed using IPLab (Scanalytics).
For immunoblotting, cellular proteins were separated electropho-
retically on a denaturing polyacrylamide gel and subsequently
transferred to a nitrocellulose membrane. The membrane was
incubated with appropriate antibodies in TBST buffer [10mMTris–HCl
(pH 8.0), 150mMNaCl, 0.05% Tween-20] containing 5% skimmilk. The
target protein bands were visualized on an X-ray ﬁlm by using
PicoWest ECL reagents (Pierce) and the signal intensity was
determined by densitometry with TINA software (Raytest). The
following antibodies were also used: HTNV N (this laboratory), HA
epitope (Sigma), actin (Santa Cruz), GFP (Santa Cruz), GAPDH (Santa
Cruz), and HRP-conjugated IgG (Amersham).
Biotinylation of cell surface proteins
Cells (∼3×107) were washed three times with cold PBS and
incubated for 20 min on ice in a solution of 5 mM sulfosuccinimidyl-
6-(biotinamido) hexanoate (sulfo-NHS-LC-biotin) (Pierce) in cold PBS
(pH 8.0). After washing the cells three times with cold PBS containing
100 mM glycine to block free biotin, cells were lysed for 10 min on ice
in modiﬁed RIPA buffer [50 mM Tris–HCl (pH 8.0), 120 mM NaCl, 0.5%
NP40, protease inhibitor cocktail (Roche)]. Cell nuclei and insoluble
debris were removed by centrifugation at 850 g for 15 min at 4 °C, and
the biotin-conjugated proteins remaining in the supernatant were
incubated in 20 μl of streptavidin–agarose (Pierce) for 1 h at 4 °C. Thebeads were washed three times with PBS, and the biotinylated
proteins were eluted with 6 M guanidine–HCl (pH 1.5), dialyzed, and
immunoblotted for gC1qR/p32.
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